サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1637054

去痰薬の世界市場 - 世界の業界分析、規模、シェア、成長、動向、予測（2032年）

Expectorant Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2032

出版日
ページ情報
英文 178 Pages
納期
2～5営業日
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.64円
去痰薬の世界市場 - 世界の業界分析、規模、シェア、成長、動向、予測（2032年）
出版日: 2025年01月14日
発行: Fairfield Market Research
ページ情報: 英文 178 Pages
納期: 2～5営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

世界の去痰薬の市場規模は、呼吸器疾患の有病率の上昇と、効果的な症状管理に関する意識の高まりに牽引され、大きな成長を遂げようとしています。CAGR4.20%での拡大が見込まれる同市場は、2025年には182億4,000万米ドル、2032年には243億2,000万米ドルに達すると予測されています。去痰薬は呼吸器ヘルスケアにおいて極めて重要な役割を果たし、慢性閉塞性肺疾患（COPD）、喘息、気管支炎などの症状を抱える患者の粘液クリアランスを促進し、呼吸の快適性を高めます。

検痰薬は、気道からの粘液の排出を促進することで、呼吸器疾患の管理に不可欠です。咳や鼻づまりを緩和する効果があるため、慢性・急性両方の呼吸器ケアに欠かせません。同市場の成長軌道は、薬剤製剤の継続的な技術革新と高度なドラッグデリバリーメカニズムの統合によって支えられています。

COPDや喘息などの慢性疾患がますます一般的になり、去痰薬の需要を牽引しています。呼吸器系の健康が世界的に優先されるようになり、これらの薬剤は症状管理の重要な一部となりつつあります。早期かつ効果的な症状管理の利点に対する認識の高まりが、市場の成長を後押ししています。予防ヘルスケアの実践では、合併症を避けるために去痰薬を適時に使用することが重視されています。製薬会社は革新的な去痰薬の開発に多額の投資を行っており、市場の可能性をさらに高めています。

当レポートでは、世界の去痰薬市場について調査し、市場の概要とともに、薬剤タイプ別、剤形別、製品タイプ別、流通チャネル別、地域別動向、および市場に参入する企業の競合動向などを提供しています。

目次

第1章 エグゼクティブサマリー

第2章 市場概要

  • 市場の定義とセグメンテーション
  • 市場力学
  • バリューチェーン分析
  • ポーターのファイブフォース分析
  • COVID-19の影響分析
  • PESTLE分析

第3章 2025年の価格分析

第4章 世界の去痰薬市場の見通し、2019年～2032年

  • 世界の去痰薬市場の見通し、薬剤タイプ別、金額（10億米ドル）、数量（100万個）、2019年～2032年
  • 世界の去痰薬市場の見通し、剤形別、金額（10億米ドル）、数量（100万個）、2019年～2032年
  • 世界の去痰薬市場の見通し、製品タイプ別、金額（10億米ドル）、数量（100万個）、2019年～2032年
  • 世界の去痰薬市場の見通し、流通チャネル別、金額（10億米ドル）、数量（100万個）、2019年～2032年
  • 世界の去痰薬市場の見通し、地域別、金額（10億米ドル）、数量（100万個）、2019年～2032年

第5章 北米の去痰薬市場の見通し、2019年～2032年

第6章 欧州の去痰薬市場の見通し、2019年～2032年

第7章 アジア太平洋の去痰薬市場の見通し、2019年～2032年

第8章 ラテンアメリカの去痰薬市場の見通し、2019年～2032年

第9章 中東・アフリカの去痰薬市場の見通し、2019年～2032年

第10章 競合情勢

  • 企業市場シェア分析、2025年
  • 競合ダッシュボード
  • 企業プロファイル
    • Abbott Laboratories
    • Acella Pharmaceuticals LLC
    • Astrazeneca Plc.
    • Cipla Limited
    • Dabur India Ltd
    • Glenmark Pharmaceuticals Limited
    • Johnson and Johnson
    • Merck KGaA
    • Novartis International AG
    • その他

第11章 付録

目次

The global expectorant drugs market is set to experience significant growth, driven by the increasing prevalence of respiratory disorders and heightened awareness regarding effective symptom management. With an anticipated expansion at a CAGR of 4.20%, the market is projected to reach USD 18.24 billion in 2025 and USD 24.32 billion by 2032. Expectorant drugs play a pivotal role in respiratory healthcare, facilitating mucus clearance and enhancing breathing comfort for patients dealing with conditions like chronic obstructive pulmonary disease (COPD), asthma, and bronchitis.

Market Insights Expectorant drugs are essential in managing respiratory ailments by promoting the expulsion of mucus from the respiratory tract. Their efficacy in alleviating coughs and congestion makes them indispensable in both chronic and acute respiratory care. The market's growth trajectory is bolstered by continuous innovation in drug formulations and the integration of advanced drug delivery mechanisms.

Key Market Drivers

  • 1. Rising Prevalence of Respiratory Disorders: Chronic conditions like COPD and asthma are increasingly common, driving demand for expectorant drugs. With respiratory health gaining priority globally, these medications are becoming a critical part of symptom management.
  • 2. Awareness of Early Intervention: Growing recognition of the benefits of early and effective symptom management is propelling market growth. Preventive healthcare practices emphasize the timely use of expectorant drugs to avoid complications.
  • 3. Research and Development Advancements: Pharmaceutical companies are investing heavily in the development of innovative expectorant formulations, further enhancing the market's potential.

Business Opportunities

  • 1. Innovative Formulations and Combination Therapies: The development of advanced drug delivery systems, such as extended-release formulations, offers promising revenue opportunities. Combination therapies incorporating expectorants with bronchodilators or anti-inflammatory agents can address multiple aspects of respiratory conditions.
  • 2. Targeted Products for Diverse Demographics: Companies can expand their product portfolios by developing specialized expectorant drugs tailored for pediatric, geriatric, and condition-specific needs. This diversification addresses a broader range of patient requirements and fosters market penetration.
  • 3. Expansion into Emerging Markets: Rapid urbanization and increasing healthcare awareness in regions like South Asia and the Pacific present lucrative opportunities for market growth.

Regional Analysis

  • 1. Europe: Europe holds a dominant position in the expectorant drugs market due to its robust healthcare infrastructure and high prevalence of respiratory disorders. Advanced medical facilities and proactive respiratory health management contribute to the region's strong foothold.
  • 2. South Asia and the Pacific: This region is anticipated to witness the fastest growth, driven by urbanization, environmental challenges, and an increasing burden of respiratory ailments. Enhanced healthcare access and rising awareness further support market expansion.
  • 3. North America and East Asia: These regions also show significant market potential, attributed to established pharmaceutical industries and growing healthcare expenditure.

Key Players The expectorant drugs market is characterized by intense competition among leading pharmaceutical companies. Notable players include:

  • Abbott Laboratories
  • Acella Pharmaceuticals LLC
  • AstraZeneca Plc.
  • Cipla Limited
  • Dabur India Ltd
  • Glenmark Pharmaceuticals Limited
  • Johnson & Johnson
  • Merck KGaA
  • Novartis International AG
  • Pfizer Inc.
  • Procter & Gamble Co.

These companies focus on strategic partnerships, innovative product launches, and geographical expansion to strengthen their market position.

Recent Developments

1. Product Launches:

    In October 2023, Efficient Laboratories introduced "ROMPR PECHITO," an OTC medicine designed for pediatric cold relief. In September 2023, Genexa launched new clean OTC kids' medicines, emphasizing safety and effectiveness, which resonated well with health-conscious consumers.

Market SegmentationThe expectorant drugs market can be categorized as follows:

1. By Drug Type:

    Secretion Enhancers: Includes potassium citrate, guaiphenesin, and ammonium chloride. Mucolytics: Comprising bromhexine, ambroxol, and acetyl cysteine.

2. By Dosage Form:

    Oral Solid: Tablets and capsules dominate due to patient convenience and precise dosing. Oral Liquid: Fast-acting formulations gaining popularity for rapid symptom relief. Inhalants: Preferred for targeted respiratory treatment.

3. By Product Type:

    Over-The-Counter (OTC): Leading segment due to accessibility and ease of use. Prescription Drugs: Essential for managing complex respiratory conditions.

4. By Distribution Channel:

    Hospital Pharmacies: Highest sales due to direct integration with healthcare facilities. Online Pharmacies: Fastest-growing segment, driven by digital convenience and accessibility. Retail Stores and Drug Stores: Continues to be a critical distribution channel.

5. By Region:

    North America Europe East Asia South Asia & Oceania Latin America Middle East & Africa

Table of Contents

1. Executive Summary

  • 1.1. Global Expectorant Drugs Market Snapshot
  • 1.2. Future Projections
  • 1.3. Key Market Trends
  • 1.4. Regional Snapshot, by Value and Volume, 2025
  • 1.5. Analyst Recommendations

2. Market Overview

  • 2.1. Market Definitions and Segmentations
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Market Opportunities
  • 2.3. Value Chain Analysis
  • 2.4. Porter's Five Forces Analysis
  • 2.5. COVID-19 Impact Analysis
    • 2.5.1. Supply
    • 2.5.2. Demand
  • 2.6. PESTLE Analysis

3. Price Analysis, 2025

  • 3.1. Global Average Price Analysis, by Drug Type/ Material, US$ Per Unit, 2025
  • 3.2. Prominent Factor Affecting Expectorant Drugs Prices
  • 3.3. Global Average Price Analysis, by Region, US$ Per Unit

4. Global Expectorant Drugs Market Outlook, 2019 - 2032

  • 4.1. Global Expectorant Drugs Market Outlook, by Drug Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 4.1.1. Key Highlights
      • 4.1.1.1. Secretion Enhancer
        • 4.1.1.1.1. Potassium Citrate
        • 4.1.1.1.2. Potassium Iodide
        • 4.1.1.1.3. Sodium Citrate
        • 4.1.1.1.4. Guaiphenesin
        • 4.1.1.1.5. Ammonium Chloride
        • 4.1.1.1.6. Others
      • 4.1.1.2. Mucolytics
        • 4.1.1.2.1. Bromhexine
        • 4.1.1.2.2. Ambroxol
        • 4.1.1.2.3. Acetyl Cysteine
        • 4.1.1.2.4. Carbocisteineurine
  • 4.2. Global Expectorant Drugs Market Outlook, by Dosage Form, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 4.2.1. Key Highlights
      • 4.2.1.1. Oral Solid
      • 4.2.1.2. Oral Liquid
      • 4.2.1.3. Inhalant
  • 4.3. Global Expectorant Drugs Market Outlook, by Product Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 4.3.1. Key Highlights
      • 4.3.1.1. Over The Counter (OTC)
      • 4.3.1.2. Prescription Drug
  • 4.4. Global Expectorant Drugs Market Outlook, by Distribution Channel, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 4.4.1. Key Highlights
      • 4.4.1.1. Hospital Pharmacies
      • 4.4.1.2. Retail Store
      • 4.4.1.3. Drug Store
      • 4.4.1.4. Online Pharmacies
  • 4.5. Global Expectorant Drugs Market Outlook, by Region, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 4.5.1. Key Highlights
      • 4.5.1.1. North America
      • 4.5.1.2. Europe
      • 4.5.1.3. Asia Pacific
      • 4.5.1.4. Latin America
      • 4.5.1.5. Middle East & Africa

5. North America Expectorant Drugs Market Outlook, 2019 - 2032

  • 5.1. North America Expectorant Drugs Market Outlook, by Drug Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 5.1.1. Key Highlights
      • 5.1.1.1. Secretion Enhancer
        • 5.1.1.1.1. Potassium Citrate
        • 5.1.1.1.2. Potassium Iodide
        • 5.1.1.1.3. Sodium Citrate
        • 5.1.1.1.4. Guaiphenesin
        • 5.1.1.1.5. Ammonium Chloride
        • 5.1.1.1.6. Others
      • 5.1.1.2. Mucolytics
        • 5.1.1.2.1. Bromhexine
        • 5.1.1.2.2. Ambroxol
        • 5.1.1.2.3. Acetyl Cysteine
        • 5.1.1.2.4. Carbocisteineurine
  • 5.2. North America Expectorant Drugs Market Outlook, by Dosage Form, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 5.2.1. Key Highlights
      • 5.2.1.1. Oral Solid
      • 5.2.1.2. Oral Liquid
      • 5.2.1.3. Inhalant
  • 5.3. North America Expectorant Drugs Market Outlook, by Product Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 5.3.1. Key Highlights
      • 5.3.1.1. Over The Counter (OTC)
      • 5.3.1.2. Prescription Drug
  • 5.4. North America Expectorant Drugs Market Outlook, by Distribution Channel, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 5.4.1. Key Highlights
      • 5.4.1.1. Hospital Pharmacies
      • 5.4.1.2. Retail Store
      • 5.4.1.3. Drug Store
      • 5.4.1.4. Online Pharmacies
  • 5.5. North America Expectorant Drugs Market Outlook, by Country, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 5.5.1. Key Highlights
      • 5.5.1.1. Expectorant Drugs Market by Drug Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 5.5.1.2. Expectorant Drugs Market by Dosage Form, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 5.5.1.3. Expectorant Drugs Market by Product Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 5.5.1.4. Expectorant Drugs Market by Distribution Channel, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 5.5.1.5. Canada Expectorant Drugs Market by Drug Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 5.5.1.6. Canada Expectorant Drugs Market by Dosage Form, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 5.5.1.7. Canada Expectorant Drugs Market by Product Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 5.5.1.8. Canada Expectorant Drugs Market by Distribution Channel, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 5.5.2. BPS Analysis/Market Attractiveness Analysis

6. Europe Expectorant Drugs Market Outlook, 2019 - 2032

  • 6.1. Europe Expectorant Drugs Market Outlook, by Drug Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 6.1.1. Key Highlights
      • 6.1.1.1. Secretion Enhancer
        • 6.1.1.1.1. Potassium Citrate
        • 6.1.1.1.2. Potassium Iodide
        • 6.1.1.1.3. Sodium Citrate
        • 6.1.1.1.4. Guaiphenesin
        • 6.1.1.1.5. Ammonium Chloride
        • 6.1.1.1.6. Others
      • 6.1.1.2. Mucolytics
        • 6.1.1.2.1. Bromhexine
        • 6.1.1.2.2. Ambroxol
        • 6.1.1.2.3. Acetyl Cysteine
        • 6.1.1.2.4. Carbocisteineurine
  • 6.2. Europe Expectorant Drugs Market Outlook, by Dosage Form, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 6.2.1. Key Highlights
      • 6.2.1.1. Oral Solid
      • 6.2.1.2. Oral Liquid
      • 6.2.1.3. Inhalant
  • 6.3. Europe Expectorant Drugs Market Outlook, by Product Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 6.3.1. Key Highlights
      • 6.3.1.1. Over The Counter (OTC)
      • 6.3.1.2. Prescription Drug
  • 6.4. Europe Expectorant Drugs Market Outlook, by Distribution Channel, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 6.4.1.1. Hospital Pharmacies
      • 6.4.1.2. Retail Store
      • 6.4.1.3. Drug Store
      • 6.4.1.4. Online Pharmacies
  • 6.5. Europe Expectorant Drugs Market Outlook, by Country, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 6.5.1. Key Highlights
      • 6.5.1.1. Germany Expectorant Drugs Market by Drug Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 6.5.1.2. Germany Expectorant Drugs Market by Dosage Form, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 6.5.1.3. Germany Expectorant Drugs Market by Product Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 6.5.1.4. Germany Expectorant Drugs Market by Distribution Channel, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 6.5.1.5. U.K. Expectorant Drugs Market by Drug Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 6.5.1.6. U.K. Expectorant Drugs Market by Dosage Form, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 6.5.1.7. U.K. Expectorant Drugs Market by Product Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 6.5.1.8. U.K. Expectorant Drugs Market by Distribution Channel, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 6.5.1.9. France Expectorant Drugs Market by Drug Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 6.5.1.10. France Expectorant Drugs Market by Dosage Form, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 6.5.1.11. France Expectorant Drugs Market by Product Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 6.5.1.12. France Expectorant Drugs Market by Distribution Channel, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 6.5.1.13. Italy Expectorant Drugs Market by Drug Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 6.5.1.14. Italy Expectorant Drugs Market by Dosage Form, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 6.5.1.15. Italy Expectorant Drugs Market by Product Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 6.5.1.16. Italy Expectorant Drugs Market by Distribution Channel, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 6.5.1.17. Turkey Expectorant Drugs Market by Drug Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 6.5.1.18. Turkey Expectorant Drugs Market by Dosage Form, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 6.5.1.19. Turkey Expectorant Drugs Market by Product Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 6.5.1.20. Turkey Expectorant Drugs Market by Distribution Channel, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 6.5.1.21. Russia Expectorant Drugs Market by Drug Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 6.5.1.22. Russia Expectorant Drugs Market by Dosage Form, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 6.5.1.23. Russia Expectorant Drugs Market by Product Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 6.5.1.24. Russia Expectorant Drugs Market by Distribution Channel, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 6.5.1.25. Rest of Europe Expectorant Drugs Market by Drug Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 6.5.1.26. Rest of Europe Expectorant Drugs Market by Dosage Form, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 6.5.1.27. Rest of Europe Expectorant Drugs Market by Product Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 6.5.1.28. Rest of Europe Expectorant Drugs Market by Distribution Channel, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 6.5.2. BPS Analysis/Market Attractiveness Analysis

7. Asia Pacific Expectorant Drugs Market Outlook, 2019 - 2032

  • 7.1. Asia Pacific Expectorant Drugs Market Outlook, by Drug Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 7.1.1. Key Highlights
      • 7.1.1.1. Secretion Enhancer
        • 7.1.1.1.1. Potassium Citrate
        • 7.1.1.1.2. Potassium Iodide
        • 7.1.1.1.3. Sodium Citrate
        • 7.1.1.1.4. Guaiphenesin
        • 7.1.1.1.5. Ammonium Chloride
        • 7.1.1.1.6. Others
      • 7.1.1.2. Mucolytics
        • 7.1.1.2.1. Bromhexine
        • 7.1.1.2.2. Ambroxol
        • 7.1.1.2.3. Acetyl Cysteine
        • 7.1.1.2.4. Carbocisteineurine
  • 7.2. Asia Pacific Expectorant Drugs Market Outlook, by Dosage Form, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 7.2.1. Key Highlights
      • 7.2.1.1. Oral Solid
      • 7.2.1.2. Oral Liquid
      • 7.2.1.3. Inhalant
  • 7.3. Asia Pacific Expectorant Drugs Market Outlook, by Product Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 7.3.1. Key Highlights
      • 7.3.1.1. Over The Counter (OTC)
      • 7.3.1.2. Prescription Drug
  • 7.4. Asia Pacific Expectorant Drugs Market Outlook, by Distribution Channel, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 7.4.1. Key Highlights
      • 7.4.1.1. Hospital Pharmacies
      • 7.4.1.2. Retail Store
      • 7.4.1.3. Drug Store
      • 7.4.1.4. Online Pharmacies
  • 7.5. Asia Pacific Expectorant Drugs Market Outlook, by Country, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 7.5.1. Key Highlights
      • 7.5.1.1. China Expectorant Drugs Market by Drug Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.2. China Expectorant Drugs Market by Dosage Form, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.3. China Expectorant Drugs Market by Product Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.4. China Expectorant Drugs Market by Distribution Channel, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.5. Japan Expectorant Drugs Market by Drug Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.6. Japan Expectorant Drugs Market by Dosage Form, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.7. Japan Expectorant Drugs Market by Product Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.8. Japan Expectorant Drugs Market by Distribution Channel, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.9. South Korea Expectorant Drugs Market by Drug Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.10. South Korea Expectorant Drugs Market by Dosage Form, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.11. South Korea Expectorant Drugs Market by Product Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.12. South Korea Expectorant Drugs Market by Distribution Channel, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.13. India Expectorant Drugs Market by Drug Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.14. India Expectorant Drugs Market by Dosage Form, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.15. India Expectorant Drugs Market by Product Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.16. India Expectorant Drugs Market by Distribution Channel, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.17. Southeast Asia Expectorant Drugs Market by Drug Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.18. Southeast Asia Expectorant Drugs Market by Dosage Form, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.19. Southeast Asia Expectorant Drugs Market by Product Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.20. Southeast Asia Expectorant Drugs Market by Distribution Channel, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.21. Rest of Asia Pacific Expectorant Drugs Market by Drug Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.22. Rest of Asia Pacific Expectorant Drugs Market by Dosage Form, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.23. Rest of Asia Pacific Expectorant Drugs Market by Product Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.24. Rest of Asia Pacific Expectorant Drugs Market by Distribution Channel, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 7.5.2. BPS Analysis/Market Attractiveness Analysis

8. Latin America Expectorant Drugs Market Outlook, 2019 - 2032

  • 8.1. Latin America Expectorant Drugs Market Outlook, by Drug Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 8.1.1. Key Highlights
      • 8.1.1.1. Secretion Enhancer
        • 8.1.1.1.1. Potassium Citrate
        • 8.1.1.1.2. Potassium Iodide
        • 8.1.1.1.3. Sodium Citrate
        • 8.1.1.1.4. Guaiphenesin
        • 8.1.1.1.5. Ammonium Chloride
        • 8.1.1.1.6. Others
      • 8.1.1.2. Mucolytics
        • 8.1.1.2.1. Bromhexine
        • 8.1.1.2.2. Ambroxol
        • 8.1.1.2.3. Acetyl Cysteine
        • 8.1.1.2.4. Carbocisteineurine
  • 8.2. Latin America Expectorant Drugs Market Outlook, by Dosage Form, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 8.2.1.1. Oral Solid
      • 8.2.1.2. Oral Liquid
      • 8.2.1.3. Inhalant
  • 8.3. Latin America Expectorant Drugs Market Outlook, by Product Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 8.3.1. Key Highlights
      • 8.3.1.1. Over The Counter (OTC)
      • 8.3.1.2. Prescription Drug
  • 8.4. Latin America Expectorant Drugs Market Outlook, by Distribution Channel, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 8.4.1. Key Highlights
      • 8.4.1.1. Hospital Pharmacies
      • 8.4.1.2. Retail Store
      • 8.4.1.3. Drug Store
      • 8.4.1.4. Online Pharmacies
  • 8.5. Latin America Expectorant Drugs Market Outlook, by Country, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 8.5.1. Key Highlights
      • 8.5.1.1. Brazil Expectorant Drugs Market by Drug Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 8.5.1.2. Brazil Expectorant Drugs Market by Dosage Form, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 8.5.1.3. Brazil Expectorant Drugs Market by Product Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 8.5.1.4. Brazil Expectorant Drugs Market by Distribution Channel, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 8.5.1.5. Mexico Expectorant Drugs Market by Drug Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 8.5.1.6. Mexico Expectorant Drugs Market by Dosage Form, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 8.5.1.7. Mexico Expectorant Drugs Market by Product Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 8.5.1.8. Mexico Expectorant Drugs Market by Distribution Channel, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 8.5.1.9. Argentina Expectorant Drugs Market by Drug Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 8.5.1.10. Argentina Expectorant Drugs Market by Dosage Form, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 8.5.1.11. Argentina Expectorant Drugs Market by Product Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 8.5.1.12. Argentina Expectorant Drugs Market by Distribution Channel, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 8.5.1.13. Rest of Latin America Expectorant Drugs Market by Drug Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 8.5.1.14. Rest of Latin America Expectorant Drugs Market by Dosage Form, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 8.5.1.15. Rest of Latin America Expectorant Drugs Market by Product Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 8.5.1.16. Rest of Latin America Expectorant Drugs Market by Distribution Channel, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 8.5.2. BPS Analysis/Market Attractiveness Analysis

9. Middle East & Africa Expectorant Drugs Market Outlook, 2019 - 2032

  • 9.1. Middle East & Africa Expectorant Drugs Market Outlook, by Drug Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 9.1.1. Key Highlights
      • 9.1.1.1. Secretion Enhancer
        • 9.1.1.1.1. Potassium Citrate
        • 9.1.1.1.2. Potassium Iodide
        • 9.1.1.1.3. Sodium Citrate
        • 9.1.1.1.4. Guaiphenesin
        • 9.1.1.1.5. Ammonium Chloride
        • 9.1.1.1.6. Others
      • 9.1.1.2. Mucolytics
        • 9.1.1.2.1. Bromhexine
        • 9.1.1.2.2. Ambroxol
        • 9.1.1.2.3. Acetyl Cysteine
        • 9.1.1.2.4. Carbocisteineurine
  • 9.2. Middle East & Africa Expectorant Drugs Market Outlook, by Dosage Form, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 9.2.1. Key Highlights
      • 9.2.1.1. Oral Solid
      • 9.2.1.2. Oral Liquid
      • 9.2.1.3. Inhalant
  • 9.3. Middle East & Africa Expectorant Drugs Market Outlook, by Product Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 9.3.1. Key Highlights
      • 9.3.1.1. Over The Counter (OTC)
      • 9.3.1.2. Prescription Drug
  • 9.4. Middle East & Africa Expectorant Drugs Market Outlook, by Distribution Channel, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 9.4.1. Key Highlights
      • 9.4.1.1. Hospital Pharmacies
      • 9.4.1.2. Retail Store
      • 9.4.1.3. Drug Store
      • 9.4.1.4. Online Pharmacies
  • 9.5. Middle East & Africa Expectorant Drugs Market Outlook, by Country, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 9.5.1. Key Highlights
      • 9.5.1.1. GCC Expectorant Drugs Market by Drug Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 9.5.1.2. GCC Expectorant Drugs Market by Dosage Form, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 9.5.1.3. GCC Expectorant Drugs Market by Product Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 9.5.1.4. GCC Expectorant Drugs Market by Distribution Channel, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 9.5.1.5. South Africa Expectorant Drugs Market by Drug Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 9.5.1.6. South Africa Expectorant Drugs Market by Dosage Form, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 9.5.1.7. South Africa Expectorant Drugs Market by Product Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 9.5.1.8. South Africa Expectorant Drugs Market by Distribution Channel, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 9.5.1.9. Egypt Expectorant Drugs Market by Drug Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 9.5.1.10. Egypt Expectorant Drugs Market by Dosage Form, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 9.5.1.11. Egypt Expectorant Drugs Market by Product Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 9.5.1.12. Egypt Expectorant Drugs Market by Distribution Channel, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 9.5.1.13. Nigeria Expectorant Drugs Market by Drug Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 9.5.1.14. Nigeria Expectorant Drugs Market by Dosage Form, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 9.5.1.15. Nigeria Expectorant Drugs Market by Product Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 9.5.1.16. Nigeria Expectorant Drugs Market by Distribution Channel, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 9.5.1.17. Rest of Middle East & Africa Expectorant Drugs Market by Drug Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 9.5.1.18. Rest of Middle East & Africa Expectorant Drugs Market by Dosage Form, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 9.5.1.19. Rest of Middle East & Africa Expectorant Drugs Market by Product Type, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 9.5.1.20. Rest of Middle East & Africa Expectorant Drugs Market by Distribution Channel, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 9.5.2. BPS Analysis/Market Attractiveness Analysis

10. Competitive Landscape

  • 10.1. Company Market Share Analysis, 2025
  • 10.2. Competitive Dashboard
  • 10.3. Company Profiles
    • 10.3.1. Abbott Laboratories
      • 10.3.1.1. Company Overview
      • 10.3.1.2. Product Portfolio
      • 10.3.1.3. Financial Overview
      • 10.3.1.4. Business Strategies and Development
    • 10.3.2. Acella Pharmaceuticals LLC
      • 10.3.2.1. Company Overview
      • 10.3.2.2. Product Portfolio
      • 10.3.2.3. Financial Overview
      • 10.3.2.4. Business Strategies and Development
    • 10.3.3. Astrazeneca Plc.
      • 10.3.3.1. Company Overview
      • 10.3.3.2. Product Portfolio
      • 10.3.3.3. Financial Overview
      • 10.3.3.4. Business Strategies and Development
    • 10.3.4. Cipla Limited
      • 10.3.4.1. Company Overview
      • 10.3.4.2. Product Portfolio
      • 10.3.4.3. Financial Overview
      • 10.3.4.4. Business Strategies and Development
    • 10.3.5. Dabur India Ltd
      • 10.3.5.1. Company Overview
      • 10.3.5.2. Product Portfolio
      • 10.3.5.3. Financial Overview
      • 10.3.5.4. Business Strategies and Development
    • 10.3.6. Glenmark Pharmaceuticals Limited
      • 10.3.6.1. Company Overview
      • 10.3.6.2. Product Portfolio
      • 10.3.6.3. Financial Overview
      • 10.3.6.4. Business Strategies and Development
    • 10.3.7. Johnson and Johnson
      • 10.3.7.1. Company Overview
      • 10.3.7.2. Product Portfolio
      • 10.3.7.3. Financial Overview
      • 10.3.7.4. Business Strategies and Development
    • 10.3.8. Merck KGaA
      • 10.3.8.1. Company Overview
      • 10.3.8.2. Product Portfolio
      • 10.3.8.3. Financial Overview
      • 10.3.8.4. Business Strategies and Development
    • 10.3.9. Novartis International AG
      • 10.3.9.1. Company Overview
      • 10.3.9.2. Product Portfolio
      • 10.3.9.3. Financial Overview
      • 10.3.9.4. Business Strategies and Development
    • 10.3.10. Others
      • 10.3.10.1. Company Overview
      • 10.3.10.2. Product Portfolio
      • 10.3.10.3. Financial Overview
      • 10.3.10.4. Business Strategies and Development

11. Appendix

  • 11.1. Research Methodology
  • 11.2. Report Assumptions
  • 11.3. Acronyms and Abbreviations